Metabolites (Dec 2022)

Alteration of Autophagy and Glial Activity in Nilotinib-Treated Huntington’s Disease Patients

  • Karen E. Anderson,
  • Max Stevenson,
  • Rency Varghese,
  • Michaeline L. Hebron,
  • Erin Koppel,
  • Mara McCartin,
  • Robin Kuprewicz,
  • Sara Matar,
  • Dalila Ferrante,
  • Charbel Moussa

DOI
https://doi.org/10.3390/metabo12121225
Journal volume & issue
Vol. 12, no. 12
p. 1225

Abstract

Read online

Nilotinib is a tyrosine kinase inhibitor that is safe and tolerated in neurodegeneration, it achieves CSF concentration that is adequate to inhibit discoidin domain receptor (DDR)-1. Nilotinib significantly affects dopamine metabolites, including Homovanillic acid (HVA), resulting in an increase in brain dopamine. HD is a hereditary disease caused by mutations in the Huntingtin’s (HTT) gene and characterized by neurodegeneration and motor and behavioral symptoms that are associated with activation of dopamine receptors. We explored the effects of a low dose of nilotinib (150 mg) on behavioral changes and motor symptoms in manifest HD patients and examined the effects of nilotinib on several brain mechanisms, including dopamine transmission and gene expression via cerebrospinal fluid (CSF) miRNA sequencing. Nilotinib, 150 mg, did not result in any behavioral changes, although it significantly attenuated HVA levels, suggesting reduction of dopamine catabolism. There was no significant change in HTT, phosphorylated neuro-filament and inflammatory markers in the CSF and plasma via immunoassays. Whole miRNA genome sequencing of the CSF revealed significant longitudinal changes in miRNAs that control specific genes associated with autophagy, inflammation, microglial activity and basal ganglia neurotransmitters, including dopamine and serotonin.

Keywords